CD350 FZD10 (frizzled homolog 10), FzE7, Fz10, hFz10, Frizzled-10
Molecule TypeAntigen ExpressionMolecular Weight
Min / Max
Non-lineage Restricted Molecule
Type 3 glycoprotein, 7 span
Kidney
Brain
Lung
Placenta
Spinal cord
Colon
Cancer cell
65 / 65

Expression

CD350 is expressed at a high level in placenta, fetal kidney and lung, and brain.  CD350 is expressed on syncytiotrophoblasts of placental villi and is highly expressed in cervical cancer cell line, HeLa S3  and colon cancer cell line, SW40.  There is expression in the cerebellum, cerebral cortex, medulla and spinal cord.  Expression is very low or weak in the adult brain, heart, skeletal muscle, pancreas, spleen and prostate. 



Structure
MOLECULAR FAMILY NAME: Belongs to the G protein-coupled receptor, Frizzed family.

CD350 is a multi-pass type-3 561 aa glycoprotein.  It contains a large 205 aa extracellular N-terminus domain which contains a cysteine-rich ligand-binding domain with 2 cys residues in the second and third extracellular loops and 2 N-linked glycosylation sites, 7 transmembrane spanning domains and a 58 aa cytoplasmic C-terminal domain which 
contains a Lys-Thr-X-X-X-Trp motif.  This motif is the binding site for PDZ-domain containing proteins and is essential foractivation of the Wntβ-catenin pathway.  The selection of intracellular signaling cascade may be determined by different C-terminal motifs in CD350 proteins.  CD350 are receptors for secreted Wnt signaling glycoproteins which are involved in developmental control.  Most frizzled receptors are coupled to the β-catenin canonical signaling pathway which leads to activation of dishevelled proteins, inhibition of GSK-3 kinase, nuclear accumulation β-catenin and activation of Wnt target genes.  A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase.  Both pathways seem to involve interactions with G-proteins.  Studies suggest that CD350 may form heterodimers.

MOLECULAR MASS

POST-TRANSCRIPTIONAL MODIFICATION: No information.

POST-TRANSLATIONAL MODIFICATION

CD350 has 2 N-linked glycosylation sites.

Ligands
LIGANDS AND MOLECULES ASSOCIATED WITH CD350

CD350 is involved in binding with Wnt proteins.

Function
CD350 is a receptor for Wnt proteins and is involved with G-proteins.  CD350 binds with Wnt ligands and participates in the activation of the Wnt/β-catenin pathway (canonical Wnt signaling).  This process is predicted to involve CD350 coupling to members of Gαi/o family of G proteins.  CD350 is essential for the regulation of tissue and cell polarity, embryonic development, regulation of proliferation and many other processes in developing and adult organisms. There is  involvement in transduction and intercellular transmission of  polarity information during tissue morphogenesis and/or in differentiated tissues.  

BIOCHEMICAL ACTIVITY: No information.

DISEASE RELEVANCE AND FUNCTION OF CD350 IN INTACT ANIMAL

Using array analysis, expression of this intronless gene CD350 is significantly up-regulated in two cases of primary colon cancer.




Comments

MOLECULAR INTERACTION-
PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD350: No information.

SUBSTRATES: No information.

ENZYMES WHICH MODIFY CD350: No information.



Database accession numbers
AnimalPIRSWISSPROTEMGBL/GENBANK
 
HumanEntrezgene11211Q9ULW2
Antibodies

Revised June 25, 2008


Contact us: Webmaster |  509-335-9515 | Accessibility | Copyright | Policies
College of Veterinary Medicine Washington State University, Pullman, WA, 99164-7010 USA
Copyright 1995-2003 Washington State University